An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety and promising objective response rates in patients with few treatment choices ...

CHICAGO — Daily adjuvant aspirin did not reduce disease recurrence for patients with colorectal cancer liver metastases and ...

Databricks also announced updates to its Unity Catalog that expand support for Apache Iceberg — the open-source table format ...

The Computer Weekly Developer Network went to AeraHUB 25 London this week, a “decision intelligence event” hosted by Aera, an ...

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

AstraZeneca Plc said a handful of patients with lupus went into remission after getting an experimental treatment, as the UK ...

A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

The most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55 ...

The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.